Enterome’s Investigational EB8018 for Crohn’s is Found Safe in Phase 1 Trial

Enterome’s Investigational EB8018 for Crohn’s is Found Safe in Phase 1 Trial
Enterome Bioscience’s EB8018, a potential new therapy for Crohn’s disease, was well-tolerated by healthy volunteers in a Phase 1 clinical trial. EB8018 targets the gut microbiome (the gut includes the alimentary tract, stomach and intestines), which is now a focus of much research because the bacteria in the gut can affect the immune system, and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *